Press release
Irritable Bowel Syndrome (IBS) Market Growth, Trends, Consumer Demand and Key Opportunities
Irritable Bowel Syndrome (IBS) Market
Irritable Bowel Syndrome (IBS) is a chronic functional gastrointestinal disorder characterized by abdominal pain, bloating, altered bowel habits (constipation, diarrhea, or mixed), and recurrent discomfort. While not life-threatening, IBS significantly reduces quality of life and is often associated with psychological distress and comorbid conditions such as anxiety and depression.
The global IBS patient pool is increasing due to stressful lifestyles, dietary changes, rising prevalence of gastrointestinal disorders, and greater awareness leading to higher diagnosis rates. Treatment approaches include antispasmodics, laxatives, anti-diarrheal drugs, probiotics, dietary therapies (e.g., low FODMAP diet), and novel targeted therapies. With expanding R&D pipelines, especially in gut-brain axis modulators, the market is set for strong growth.
In 2024, the global Irritable Bowel Syndrome Market is valued at USD 3.4 billion and is projected to reach USD 6.5 billion by 2034, growing at a CAGR of 6.7% (2025-2034).
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/71120
Market Overview
• Market Size 2024: USD 3.4 billion
• Forecast 2034: USD 6.5 billion
• CAGR (2025-2034): 6.7%
• Key Drivers: Increasing prevalence of IBS, rising healthcare awareness, strong pipeline of novel therapies, and greater adoption of probiotics and dietary approaches.
• Key Challenges: Lack of curative treatment, variability in patient response, social stigma, and underdiagnosis in emerging markets.
• Leading Players: AbbVie, Ironwood Pharmaceuticals, Takeda, Novartis, Johnson & Johnson, GlaxoSmithKline, AstraZeneca, Bayer AG, Allergan (AbbVie), Bausch Health.
The IBS market is transitioning toward precision treatment approaches, leveraging microbiome research and targeted therapies.
Segmentation Analysis
By Product
• Antispasmodics
• Laxatives
• Anti-diarrheal drugs
• Probiotics and nutraceuticals
• Antidepressants and gut-brain modulators
• Novel targeted therapies
By Therapy
• Pharmacological therapy
• Nutritional and dietary therapy
• Behavioral therapy (psychological support, CBT)
• Combination therapy
By Distribution Channel
• Hospital pharmacies
• Retail pharmacies
• Specialty clinics
• Online pharmacies
By End-Use
• Hospitals
• Gastroenterology clinics
• Research institutes
• Homecare
By Application
• IBS with constipation (IBS-C)
• IBS with diarrhea (IBS-D)
• Mixed IBS (IBS-M)
• Unclassified IBS
Summary of Segmentation
Currently, IBS-C and IBS-D therapies dominate, with linaclotide, lubiprostone, and rifaximin widely used. However, probiotics and microbiome-targeted therapies are expected to be the fastest-growing category, reflecting increasing patient preference for safer, non-invasive options.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/71120/irritable-bowel-syndrome-market
Regional Analysis
• North America: Largest market share, driven by strong diagnosis rates, high healthcare spending, and adoption of novel IBS drugs such as linaclotide (Linzess).
• Europe: Strong growth due to well-established gastroenterology networks, reimbursement support, and dietary therapy adoption.
• Asia-Pacific: Fastest-growing region (CAGR >7%), fueled by rising prevalence of IBS, changing dietary patterns, and increasing healthcare access in China, India, and Japan.
• Middle East & Africa: Moderate growth, hindered by underdiagnosis and limited healthcare infrastructure, though awareness programs are improving.
• Latin America: Brazil and Mexico lead growth, with increasing awareness and gradual expansion of IBS treatment protocols.
Regional Trends Summary
While North America and Europe dominate today, Asia-Pacific is emerging as the fastest-growing region, driven by lifestyle changes, higher diagnosis rates, and growing pharmaceutical investment.
Market Dynamics
Key Growth Drivers
• Rising global prevalence of IBS due to dietary and lifestyle factors.
• Growing demand for probiotics and microbiome-targeted therapies.
• Expanding clinical trials in gut-brain modulators and novel drugs.
• Increasing patient awareness and acceptance of IBS as a treatable condition.
Key Challenges
• Lack of universally effective therapies.
• Variable patient response and symptom overlap with other GI disorders.
• Stigma and underreporting, especially in emerging economies.
• High reliance on symptomatic treatments rather than curative options.
Latest Trends
• Growing adoption of linaclotide (Linzess) and eluxadoline (Viberzi).
• Increased research into microbiome-based diagnostics and therapeutics.
• Integration of digital health tools and mobile apps for symptom tracking.
• Expansion of dietary interventions, particularly low FODMAP diets.
Get Your Exclusive Offer with up to 10% Discount:
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71120
Competitive Landscape
Major Players
• AbbVie
• Ironwood Pharmaceuticals
• Takeda
• Novartis
• Johnson & Johnson
• GlaxoSmithKline
• AstraZeneca
• Bayer AG
• Allergan (AbbVie)
• Bausch Health
Competitive Insights
The IBS market is moderately consolidated, with AbbVie and Ironwood leading in IBS-C treatments through Linzess (linaclotide). Takeda and Allergan are active in IBS-D therapies. Emerging biotech firms are investing in microbiome research and novel gut-brain therapies, which are expected to disrupt the market by 2030+. Strategic partnerships and licensing deals are key growth strategies.
Conclusion
The global Irritable Bowel Syndrome Market is expanding rapidly, driven by rising prevalence, growing awareness, and therapeutic innovation. From USD 3.4 billion in 2024 to USD 6.5 billion by 2034, the market is projected to grow at a CAGR of 6.7%.
• Opportunities: Asia-Pacific expansion, microbiome-targeted therapies, and digital IBS management tools.
• Challenges: Lack of curative therapies, underdiagnosis, and treatment variability.
• Key Takeaway: Companies that invest in next-generation gut-brain therapies, microbiome-based solutions, and holistic IBS management approaches will lead the market transformation in the coming decade.
This report is also available in the following languages : Japanese (過敏性腸症候群市場), Korean (과민성 대장 증후군 시장), Chinese (肠易激综合征市场), French (Marché du syndrome du côlon irritable), German (Markt für Reizdarmsyndrom), and Italian (Mercato della sindrome dell'intestino irritabile), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71122
Our More Reports:
Dermatomyositis Patient Pool Market
https://exactitudeconsultancy.com/reports/71100/dermatomyositis-patient-pool-market
Stress urinary incontinence Patient Pool Market
https://exactitudeconsultancy.com/reports/71098/stress-urinary-incontinence-patient-pool-market
Homozygous Familial Hypercholesterolemia Patient Pool Market
https://exactitudeconsultancy.com/reports/71096/homozygous-familial-hypercholesterolemia-patient-pool-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
IRFAN TAMBOLI
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Irritable Bowel Syndrome (IBS) Market Growth, Trends, Consumer Demand and Key Opportunities here
News-ID: 4158177 • Views: …
More Releases from Exactitude Consultancy
Gastroparesis Market Set to Witness Significant Growth by 2025-2034
Introduction
Gastroparesis is a chronic gastrointestinal motility disorder characterized by delayed gastric emptying without mechanical obstruction. It leads to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal discomfort, often resulting in malnutrition and reduced quality of life.
The most common cause of gastroparesis is diabetes mellitus, particularly poorly controlled type 1 and type 2 diabetes. Other causes include post-surgical complications, neurological conditions, and idiopathic cases. With the global rise in…
Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Trends, Epid …
Metabolic Dysfunction-Associated Steatohepatitis (MASH), formerly referred to as Non-Alcoholic Steatohepatitis (NASH), is a progressive form of fatty liver disease characterized by fat accumulation, inflammation, hepatocyte injury, and varying degrees of fibrosis. It is closely linked to obesity, type 2 diabetes, metabolic syndrome, and cardiovascular risk factors.
MASH/NASH is a major global health burden, with prevalence rising due to the global obesity epidemic and sedentary lifestyles. If untreated, it can progress to…
Gastrointestinal Neuroendocrine Tumors (GI-NETs) Market Insights and Future Outl …
Gastrointestinal Neuroendocrine Tumors (GI-NETs) Market Outlook 2024-2034: Advancing Diagnostics and Targeted Therapies to Drive Growth
Introduction
Gastrointestinal Neuroendocrine Tumors (GI-NETs) are rare malignancies that originate from neuroendocrine cells in the gastrointestinal tract, including the stomach, small intestine, colon. These tumors can be functioning (hormone-secreting) or non-functioning, often leading to late diagnoses. Symptoms vary widely and may include abdominal pain, diarrhea, flushing, and in advanced cases, metastasis to the liver.
Historically considered rare and…
Liver Cirrhosis Market Trends, Epidemiology and Future Outlook
Liver cirrhosis is a chronic, progressive liver disease characterized by scarring (fibrosis) and the gradual replacement of healthy liver tissue with scar tissue. This disrupts normal liver function, leading to portal hypertension, liver failure, and complications such as ascites, variceal bleeding, hepatic encephalopathy, and hepatocellular carcinoma (HCC).
The global burden of cirrhosis is rising due to the increasing prevalence of alcoholic liver disease, chronic hepatitis B and C, and non-alcoholic fatty…
More Releases for IBS
Irritable Bowel Syndrome (IBS) Treatment Market Poised to Hit $7.68B by 2033 | S …
The Global Irritable Bowel Syndrome (IBS) Treatment Market reached US $3.61 billion in 2024 and is forecast to nearly double to US $7.68 billion by 2033, growing at a robust 8.8% CAGR from 2025 to 2033, according to DataM Intelligence's comprehensive report. IBS affects an estimated 5-10% of the global population, marking it one of the most prevalent gastrointestinal disorders with significant unmet medical needs.
👉 Download our latest market insights:…
Integrated Bridge Systems Market Report 2018: Segmentation by Platform (Commerci …
Global Integrated Bridge Systems market research report provides company profile for Northrop Grumman Sperry Marine (U.K.), Raytheon Anschütz (Germany), Rolls Royce (U.K.), L-3 Communications Mapps Inc. (Canada), FURUNO Electric Shokai Ltd. (Japan) and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR…
IBS' solution to power China’s first Cruise Line
Trivandrum, 16 January 2013: Henna, the largest cruise ship in mainland China will run on IBS’ inventory and pricing management solution, Cruise Partner, when it makes its maiden journey on January 26, 2013. China based HNA Tourism Cruise and Yacht Management Company unveiled this cruise ship on November 28, 2012. Henna has 739 rooms for 1,965 passengers, as well as a complete range of facilities for living and entertainment. HNA…
Vikash Sureka joins IBS as Chief Financial Officer
Trivandrum (India), 17 May 2012: IBS Software Services, the leading provider of new-generation IT solutions to the global aviation industry, has appointed Mr Vikash Sureka as its Chief Financial Officer. He will head the Finance, Legal, Company Affairs and Administration functions of IBS operations world-wide.
A Chartered Accountant, Vikash has over 19 years of experience mostly in senior executive roles managing business globally with proven proficiency in Investor Relations, P&L…
HaCon and IBS combine expertise in railway operation
Hanover (2010-07-06). Two Hanoverian companies now combine their expertise in questions of railway operations: With effect from 1 July 2010, the HaCon Ingenieurgesellschaft mbH, took over the engineering firm for railway operating systems (Ingenieurbüro für Bahnbetriebssysteme GmbH – IBS). This way HaCon expanded its services to include the areas operation simulation, vehicle and personnel planning and construction operations planning.
This also includes consulting services concerning railway systems issues, such as travel…
Raytheon Anschütz IBS for new Intership Bulkers
Raytheon Anschütz was recently awarded a contract to supply their Integrated Bridge System (IBS) to two new bulk carriers. The bulkers will be built at New Times Shipyard in Jingjiang, China. The delivery to the Cyprus based shipping company Intership Navigation Co. Ltd., a member of the German Hartmann Group, is scheduled for August and October 2011.
The new bulkers, each with a capacity of 176,000 dwt, will be equipped…
